VCEL · Insider Trading
Vericel Corporation
Every open-market purchase and sale reported by VCEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-14 | Kevin F McLaughlin | Director | MIXED | — | −$220.36K |
| 2026-08-05 | Michael Halpin | Chief Operating Officer | MIXED | — | −$301.80K |
| 2026-07-31 | Jonathan Siegal | Principal Accounting Officer | MIXED | — | −$78.24K |
| 2026-06-22 | Sean C. Flynn | Chief Legal Officer | MIXED | — | −$359.40K |
| 2026-06-22 | Michael Halpin | Chief Operating Officer | MIXED | — | −$235.80K |
| 2026-06-04 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | −$80.24K |
| 2026-05-15 | Kevin F McLaughlin | Director | MIXED | — | −$174.90K |
| 2026-05-13 | Paul K Wotton | Director | Sell | −10,000 | −$327.43K |
| 2026-05-08 | Joseph Anthony Mara Jr | Chief Financial Officer | Sell | −5,000 | −$202.50K |
| 2026-05-08 | Jonathan Siegal | Principal Accounting Officer | Sell | −4,855 | −$188.04K |
| 2026-05-01 | Paul K Wotton | Director | M | +3,200 | — |
| 2026-05-01 | Kevin F McLaughlin | Director | M | +3,200 | — |
| 2026-05-01 | Heidi Hagen | Director | M | +3,200 | — |
| 2026-05-01 | Alan L Rubino | Director | M | +3,200 | — |
| 2026-05-01 | Lisa Wright | Director | M | +3,200 | — |
| 2026-05-01 | Robert L Md Zerbe | Director | M | +3,200 | — |
| 2026-04-06 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | −$83.50K |
| 2026-03-27 | Alan L Rubino | Director | M | +15,000 | +$41.40K |
| 2026-03-25 | Heidi Hagen | Director | MIXED | — | −$444.75K |
| 2026-03-04 | Michael Halpin | Chief Operating Officer | Sell | −10,305 | −$363.77K |
| 2026-03-04 | Sean C. Flynn | Chief Legal Officer | MIXED | −6,421 | −$509.78K |
| 2026-02-26 | Joseph Anthony Mara Jr | Chief Financial Officer | MIXED | +6,534 | −$103.67K |
| 2026-02-26 | Sean C. Flynn | Chief Legal Officer | MIXED | +3,616 | −$110.06K |
| 2026-02-26 | Michael Halpin | Chief Operating Officer | MIXED | +5,528 | −$189.78K |
| 2026-02-26 | Dominick Colangelo | President and CEO | MIXED | +27,676 | −$336.11K |
| 2026-02-26 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | +4,529 | −$75.18K |
| 2026-02-26 | Jonathan Siegal | Principal Accounting Officer | MIXED | +2,050 | −$52.11K |
| 2026-02-20 | Michael Halpin | Chief Operating Officer | MIXED | +4,777 | −$159.32K |
| 2026-02-20 | Sean C. Flynn | Chief Legal Officer | MIXED | +2,805 | −$93.39K |
| 2026-02-20 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | +4,343 | −$36.74K |
| 2026-02-20 | Joseph Anthony Mara Jr | Chief Financial Officer | MIXED | +5,066 | −$85.68K |
| 2026-02-20 | Dominick Colangelo | President and CEO | MIXED | +24,293 | −$211.63K |
| 2026-02-20 | Jonathan Siegal | Principal Accounting Officer | MIXED | +1,615 | −$48.16K |
| 2026-02-13 | Kevin F McLaughlin | Director | MIXED | — | −$224.21K |
| 2026-01-09 | Michael Halpin | Chief Operating Officer | MIXED | — | −$238.20K |
| 2025-12-12 | Karen Mahoney | Chief Human Resources Officer | MIXED | +1,854 | −$29.28K |
| 2025-12-04 | Paul K Wotton | Director | Sell | −5,000 | −$189.50K |
| 2025-12-04 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | −$34.92K |
| 2025-11-13 | Michael Halpin | Chief Operating Officer | MIXED | — | −$62.75K |
| 2025-11-12 | Kevin F McLaughlin | Director | MIXED | — | −$251.72K |
| 2025-11-10 | Michael Halpin | Chief Operating Officer | MIXED | — | −$175.19K |
| 2025-10-02 | Jonathan Siegal | Principal Accounting Officer | MIXED | +568 | −$11.64K |
| 2025-09-03 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | −$177.70K |
| 2025-08-08 | Kevin F McLaughlin | Director | MIXED | — | −$232.12K |
| 2025-06-04 | Jonathan Mark Hopper | Chief Medical Officer | MIXED | — | −$220.90K |
| 2025-05-16 | Dominick Colangelo | President and CEO | MIXED | — | −$1.10M |
| 2025-05-09 | Kevin F McLaughlin | Director | MIXED | — | −$260.54K |
| 2025-05-02 | Karen Mahoney | Chief Human Resources Officer | A | +5,175 deriv. | — |
| 2025-05-02 | Heidi Hagen | Director | M | +3,200 | — |
| 2025-05-02 | Robert L Md Zerbe | Director | M | +3,200 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Dominick Colangelo | President and CEO | 303,020 | $12.69M |
| Jonathan Mark Hopper | Chief Medical Officer | 80,128 | $3.36M |
| Alan L Rubino | Director | 64,234 | $2.69M |
| Heidi Hagen | Director | 35,050 | $1.47M |
| Robert L Md Zerbe | Director | 32,995 | $1.38M |
| Michael Halpin | Chief Operating Officer | 32,753 | $1.37M |
| Joseph Anthony Mara Jr | Chief Financial Officer | 21,009 | $879.75K |
| Paul K Wotton | Director | 18,802 | $787.33K |
| Kevin F McLaughlin | Director | 18,300 | $766.31K |
| Sean C. Flynn | Chief Legal Officer | 16,647 | $697.09K |
| Lisa Wright | Director | 15,851 | $663.76K |
| Karen Mahoney | Chief Human Resources Officer | 2,625 | $109.92K |
| Jonathan Siegal | Principal Accounting Officer | 1,578 | $66.08K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VCEL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.